We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+30.25%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$12B
AUM Growth
+$2.23B
Cap. Flow
-$2.3B
Cap. Flow %
-19.15%
Top 10 Hldgs %
76.74%
Holding
140
New
18
Increased
23
Reduced
51
Closed
10

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$121M
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$106M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$76.4M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$51.5M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$34.6M

Top Sells

Rank Stock Value
1
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$653M
2
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$73M
3
VNDA icon
Vanda Pharmaceuticals
VNDA
+$30.8M
4
PCYC
PHARMACYCLICS INC
PCYC
+$17.3M
5
XOMA
Xoma
XOMA
+$8.13M

Sector Composition

Rank Sector Weight
1 Healthcare 45.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMGN
51
DELISTED
Immunogen Inc
IMGN
$8.95M 0.07%
+999,496
New +$7.24M
OSIR
52
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$8.78M 0.07%
499,193
-11,413
-2% -$192K
PRQR icon
53
ProQR Therapeutics
PRQR
$330M
$8.75M 0.07%
400,000
– –
ARWR icon
54
Arrowhead Research
ARWR
$12.3B
$8.73M 0.07%
1,290,187
+59,385
+5% +$421K
VIRX
55
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$7.84M 0.07%
15,238
– –
LJPC
56
DELISTED
La Jolla Pharmaceutical Company
LJPC
$7.54M 0.06%
412,008
-9,623
-2% -$195K
CNCE
57
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$7.51M 0.06%
495,908
-9,510
-2% -$133K
EIGR
58
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$6.95M 0.06%
815
-18
-2% -$157K
KPTI icon
59
Karyopharm Therapeutics
KPTI
$44.5M
$6.64M 0.06%
14,466
+8,193
+131% +$3.53M
JUNO
60
DELISTED
Juno Therapeutics, Inc.
JUNO
$6.07M 0.05%
100,000
– –
FMI
61
DELISTED
Foundation Medicine, Inc.
FMI
$5.98M 0.05%
124,255
-1,892
-1% -$85.8K
RXDX
62
DELISTED
Ignyta, Inc.
RXDX
$5.68M 0.05%
571,000
– –
LGND icon
63
Ligand Pharmaceuticals
LGND
$5.71B
$5.66M 0.05%
117,638
-22
-0% -$843
TTHI
64
DELISTED
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
$5.25M 0.04%
+769,230
New +$5.31M
AMRN
65
Amarin Corp
AMRN
$298M
$5.16M 0.04%
+110,286
New +$3.37M
STML
66
DELISTED
Stemline Therapeutics, Inc.
STML
$4.83M 0.04%
333,497
-5,174
-2% -$79.2K
CYTR
67
DELISTED
CytRx Corp
CYTR
$4.45M 0.04%
219,998
-5,002
-2% -$93.1K
EPZM
68
DELISTED
Epizyme, Inc
EPZM
$4.37M 0.04%
232,481
+30,518
+15% +$630K
CMRX
69
DELISTED
Chimerix, Inc.
CMRX
$4.34M 0.04%
115,216
-57,198
-33% -$2.27M
INFI
70
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$4.26M 0.04%
305,037
-6,988
-2% -$107K
WINT
71
DELISTED
Windtree Therapeutics Inc
WINT
$4.25M 0.04%
254,975
-5,891
-2% -$116K
RCPT
72
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$3.94M 0.03%
23,900
– –
SAGE
73
DELISTED
Sage Therapeutics
SAGE
$3.77M 0.03%
75,000
– –
LRMR icon
74
Larimar Therapeutics
LRMR
$434M
$3.75M 0.03%
+7,895
New +$3.75M
IONS icon
75
Ionis Pharmaceuticals
IONS
$9.93B
$3.64M 0.03%
57,140
-39,163
-41% -$2.66M
1 2
3
4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q1 2015 Portfolio in Review

As of Q1 2015, Julian Baker held 140 positions worth $12B, up 23% from $9.8B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Julian Baker withdrew a net $2.3B in Q1 2015, closing 10 positions and reducing 51 holdings. Its most notable exit was AVANIR PHARMACEUTICALS, INC CL A, an estimated $653M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 47% a quarter earlier.

Against the trend, Julian Baker opened a new position in Invitae Corporation worth $110M.

  • Julian Baker's largest Q1 2015 buy was Invitae Corporation: 6,554,967 shares worth $110M.
  • Julian Baker added most to SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2015, an estimated $106M increase.
  • Julian Baker's biggest Q1 2015 reduction was Vanda Pharmaceuticals, cutting an estimated $30.8M.
  • Julian Baker fully exited AVANIR PHARMACEUTICALS, INC CL A in Q1 2015, selling an estimated $653M.
  • Julian Baker's ten largest holdings make up 77% of its $12B portfolio in Q1 2015.
  • Julian Baker opened 18 new positions and closed 10 in Q1 2015.
  • Julian Baker's portfolio value rose 23% quarter-over-quarter to $12B.

Based on Baker Bros. Advisors's 13F filing for Q1 2015, filed 15 May 2015.